182 related articles for article (PubMed ID: 27799749)
1. Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.
Katz EG; Hauber B; Gopal S; Fairchild A; Pugh A; Weinstein RB; Levitan BS
Patient Prefer Adherence; 2016; 10():2127-2139. PubMed ID: 27799749
[TBL] [Abstract][Full Text] [Related]
2. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
[TBL] [Abstract][Full Text] [Related]
3. Attitudes of European physicians towards the use of long-acting injectable antipsychotics.
Patel MX; Bent-Ennakhil N; Sapin C; di Nicola S; Loze JY; Nylander AG; Heres S
BMC Psychiatry; 2020 Mar; 20(1):123. PubMed ID: 32169077
[TBL] [Abstract][Full Text] [Related]
4. Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia.
Robinson DG; Suett M; Wilhelm A; Chaijale N; Franzenburg KR; Gandhi S; Cloud B; Mychaskiw M
Adv Ther; 2023 May; 40(5):2249-2264. PubMed ID: 36905498
[TBL] [Abstract][Full Text] [Related]
5. Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment.
Levitan B; Markowitz M; Mohamed AF; Johnson FR; Alphs L; Citrome L; Bridges JF
Psychiatr Serv; 2015 Jul; 66(7):719-26. PubMed ID: 25772762
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
10. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
11. Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.
Blackwood C; Sanga P; Nuamah I; Keenan A; Singh A; Mathews M; Gopal S
Patient Prefer Adherence; 2020; 14():1093-1102. PubMed ID: 32753849
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
[TBL] [Abstract][Full Text] [Related]
13. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
14. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
Morris MT; Tarpada SP
Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
[TBL] [Abstract][Full Text] [Related]
15. A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly.
Geerts H; Spiros A; Roberts P; Alphs L
Schizophr Res; 2018 Jul; 197():261-268. PubMed ID: 29395607
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists' survey in India.
Gundugurti PR; Nagpal R; Sheth A; Narang P; Gawande S; Singh V
Asian J Psychiatr; 2017 Dec; 30():88-93. PubMed ID: 28843143
[TBL] [Abstract][Full Text] [Related]
17. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L
Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793
[TBL] [Abstract][Full Text] [Related]
19. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies.
Gopal S; Xu H; McQuarrie K; Savitz A; Nuamah I; Woodruff K; Mathews M
NPJ Schizophr; 2017 Jul; 3(1):23. PubMed ID: 28751663
[TBL] [Abstract][Full Text] [Related]
20. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
[No Abstract] [Full Text] [Related]
[Next] [New Search]
